Brief: Milestone Pharmaceuticals Announces Publication Of Results From Phase 3 RAPID Clinical Trial Of Etripamil Nasal Spray In Patients With PSVT In The Lancet
20/06/2023 12:06
June 20 (Reuters) - Milestone Pharmaceuticals Inc
MIST.O :
* MILESTONE PHARMACEUTICALS ANNOUNCES PUBLICATION OF RESULTS
FROM
PHASE 3 RAPID CLINICAL TRIAL OF ETRIPAMIL NASAL SPRAY IN
PATIENTS WITH PSVT IN THE LANCET
* MILESTONE PHARMACEUTICALS INC - NDA SUBMISSION FOR
ETRIPAMIL IN
PATIENTS WITH PSVT ON TRACK FOR 3Q23
* MILESTONE PHARMACEUTICALS - SAFETY AND TOLERABILITY
PROFILE OF
REPEAT-DOSE REGIMEN CONSISTENT WITH PREVIOUSLY STUDIED
SINGLE-DOSE SELF-ADMINISTRATION
* MILESTONE PHARMACEUTICALS INC - PRIMARY ENDPOINT MET
Source text for Eikon: ID:nPnmKNTta
Further company coverage: MIST.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview